Contrast-enhanced Computed Tomography and Acute Kidney Injury

NCT07091656 | Completed

• 1 other identifier: urgBjNPC-AKI
• Study Type: observational
• Target: 1,463
• Locations: 1 country
• Sites: 1

Brief Summary

Rationale and objectives: Since 1930 it has been accepted that intravenous injection of io-dinated contrast agent as part of contrast-enhanced computed tomography (CE-CT) imaging can induce a contrast-associated acute kidney injury (CA-AKI). For the last 10 years, studies have investigated this iatrogenia. However, those works didn't concern French population and particularly patient hospitalised after emergency department (ED) visit. This study as-sessed the CA-AKI incidence and factor risks in patients hospitalised after a CE-CT in ED. This was a retrospective cohort observational study in the ED of the Beaujon University Hospital between October 31st 2019 to January 24th 2022. Patients over 16 years old who presented to the emergency department and underwent an intravenous contrast-enhanced CT were eligible. To be included, patients were required to have at least two creatinine measurements: one taken within 24 hours before CT and a second measurement taken between 48 hours to the seventh day following the initial test. The CT examination had to be performed at Beaujon Hospital with the injection of iodinated contrast agents such as IOMERON® (iomeprol) or XENETIX® (iobitridol).

Conditions

Contrast-associated Acute Kidney Injury

Keywords

Acute kidney injury; contrast media; tomography; ontrast-induced nephropathy

Outcome Measures

Primary Outcomes (1)

• The primary outcome was the occurrence of CA-AKI defined as KDIGO (Kidney Disease Improval Global Outcomes) tage 1 or higher within seven days after contrast-enhanced CT.

  BETWEEN 2 and 7 DAYS ATER CT -SCAN

Interventions

there is no intervention OTHER

NO INTERVENTION

Eligibility Criteria

• Age: 16 Years+
• Sex: all
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients over 16 years old who presented to the emergency department and underwent an intravenous contrast-enhanced CT were eligible.

You may qualify if:

• Patients over 16 years old who presented to the emergency department and underwent an intravenous contrast-enhanced CT were eligible. To be included, patients were required to have at least two creatinine measurements: one taken within 24 hours before CT and a sec-ond measurement taken between 48 hours to the seventh day following the initial test. The CT examination had to be performed at Beaujon Hospital with the injection of iodinated contrast agents such as IOMERON® (iomeprol) or XENETIX® (iobitridol).

You may not qualify if:

• Patients were excluded from the study if they did not have two creatinine measurements meeting the specified criteria. If multiple contrast-enhanced CT examinations were per-formed within a seven-day period for the same patient, only the first examination was in-cluded in the study, while subsequent scans were excluded.

Sponsors & Collaborators

• Beaujon Hospital: lead

Study Sites (1)

Hopital Beaujon

Clichy, Île-de-France (Paris), 92110, France

Location

Related Publications (1)

• Lecomte E, Vaittinada Ayar P, Vilgrain V, Vaittinada Ayar P. Incidence and risk factors of contrast-associated acute kidney injury in patients hospitalised after contrast-enhanced computed tomography in the emergency department. Int J Emerg Med. 2025 Dec 29;18(1):265. doi: 10.1186/s12245-025-01058-0.

  PMID: 41462065 DERIVED

MeSH Terms

Conditions

Acute Kidney Injury

Condition Hierarchy (Ancestors)

Renal Insufficiency; Kidney Diseases; Urologic Diseases; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: MD, PhD

Study Record Dates

• First Submitted: July 22, 2025
• First Posted: July 29, 2025
• Study Start: October 31, 2019
• Primary Completion: January 24, 2022
• Study Completion: December 31, 2022
• Last Updated: July 29, 2025

Record last verified: 2025-07

Data Sharing

• IPD Sharing: Will not share

Locations

FR (1)